Best Hematology Specialists in Brooklyn, NY

It is a privilege to take care of patients with breast cancer. Each patient is different, each breast cancer is different and treatment recommendations are tailored to the individual patient. At the Weill Cornell Breast Center, we work as a team to recommend the optimal treatment plan for each patient. We have begun a new initiative, a "survivorship" program to study and support our patients throughout their lifetime after a breast cancer diagnosis. It is exciting to be in the forefront of breast cancer research not only with our own group at the Breast Center but also as part of the exciting research going on across the nation. Every year brings advances in this field. I am very happy to be part of it!

The ability to work closely with patients and with specialists in a variety of fields to solve complex clinical questions draws me to the field of non-malignant hematology. I am lucky to have had the opportunity to train under brilliant thinkers and exceptional role models from whom I have learned the importance of ensuring that each patient truly understands his or her diagnosis and the rationale behind treatment. I am excited to be joining the Department of Hematology at Weill Cornell and look forward to continuing in clinical investigations in hopes of improving diagnosis and treatment in the fields of thrombosis and immune thrombocytopenia. We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Everything that we do at our center, whether clinical care, research or education, is focused on helping patients. Here are some of the many reasons why patients tell us they come here - whether from the New York area, the surrounding region, or traveling from all over the country and other parts of the world in order to receive evaluation and treatment for lymphoma by our group. Patients seek treatment here because they are referred here by their physicians, who recognize our expertise and know that across the region and the country we are a "go to" place to seek the best lymphoma care. Our physicians are internationally recognized for clinical skill, research, and personal qualities. In fact, we care for a substantial number of individual physicians (or their family members) who are themselves dealing with lymphoma.

Michael S. Samuel, M.D. is an Assistant Professorof Clinical Medicine at Weill Cornell Medical College and Assistant Attending Physician at New York Presbyterian Hospital. Dr. Samuel took an indirect route to medicine, initially receiving his B.A. in English and Anthropology from Union College. He worked as a treatment counselor for developmentally disabled at-risk youth, and then as a teacher of English as a foreign language in Shenzhen, China.Dr. Samuel subsequently joined the leukemia program at Weill Cornell Medical College as a clinical trials research assistant while completing post-baccalaureate studies at Columbia University. He then received his MD from SUNY Downstate Medical Center College of Medicine in 2009. Thereafter, Dr. Samuel completed both his residency in internal medicine and fellowship in Hematology/Oncology at Montefiore Medical Center. His medical training also included experiences studying acupuncture in Beijing, China, and service as a physician on the medical ward at Kisoro District Hospital in Uganda.Throughout his medical training Dr. Samuel maintained a focus on hematological malignancies and spent his final year of fellowship in the lab of Kira Gritsman, MD, PhD, at Albert Einstein Cancer Center studying the genetic determinants of PI3 kinase pathway dependence in leukemic development. Dr. Samuel now rejoins the Leukemia Program in the division of Hematology/Oncology at Weill Cornell Medical College where he will specialize in the treatment of patients with leukemia, myelodysplasia and myeloproliferative neoplasms, and will be actively involved in the clinical trials research within the program.

Dr. Furman is Director of the CLL Research Center at Weill Cornell Medicineand a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology. His area of focus is on the development of non-chemotherapeutic approaches to treating CLL, and has played an integral part in the development of ibrutinib and idelalisib.For More Videos, please see below:Lymphoma Cancer Treatment NY - Weill Cornell

Dr. Ritchie's research interests are in the treatment of older patients with anemia, cytopenias, myelodysplastic syndromes, myeloproliferative disorders and acute leukemia. She is interested in finding better therapies and supportive care strategies for older patients. Dr. Ritchie is the principal investigator on clincal trials investigating new diagnostic techniques, supportive care strategies and therapeutics aimed at the older patient. She collaborates with investigators in the Division of Geriatrics and Gerontology. She has been the author or co-author of many publications. She is interested in improving the medical care of older patients with hematologic malignancies.

My first priority is the patient sitting in front of me. I have a longstanding interest in cancer care and have been specifically focused on lymphoma since my father was diagnosed with Hodgkin lymphoma when I was a medical student. At Weill Cornell, our experienced team of lymphoma specialists works together to determine the most appropriate therapy for each individual patient. Our group has played a key role in the development of many new therapies approved for lymphoma in recent years. As a result, our patients have early access to new and promising lymphoma treatments. We are fortunate to have a strong team of physician assistants, nurses, medical technicians, pharmacists, and administrative staff. This environment enables me to provide my patients with the best possible level of care.

One of the most gratifying aspects of practicing at Weill Cornell has been the close collaborations with talented clinicians and scientists in the diagnosis and management of complex blood disorders. In my new role, I look forward to providing the same personal care to my patients utilizing the latest diagnostic tools and therapeutic modalities to improve patient outcomes.